Myelodysplastic Syndrome Clinical Trials in New York, New York

6 studies are recruiting for myelodysplastic syndrome in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

   This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrom…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mount Sinai Hospital, New York, New York

   Locations

   349 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564390 on ClinicalTrials.gov

2. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

   This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

   Stage

   Phase 1

   Ages

   Up to 22

   Site

   NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York

   Locations

   184 in total

   Run by

   PedAL BCU, LLC

   See if you can join NCT04726241 on ClinicalTrials.gov

3. Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

   This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   22 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06484062 on ClinicalTrials.gov

4. Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

   The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Irving Medical Center, New York, New York

   Locations

   16 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06419634 on ClinicalTrials.gov

5. Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

   The main goals of this study are to learn if RPT1G is safe and tolerable and to determine the best dose and schedule of RPT1G for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   2 in total

   Run by

   Remedy Plan, Inc.

   See if you can join NCT07107126 on ClinicalTrials.gov

6. A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

   This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will be done i…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan-Kettering Cancer Center, New York, New York

   Locations

   3 in total

   Run by

   Edgewood Oncology Inc.

   See if you can join NCT04243785 on ClinicalTrials.gov